for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Fagron NV

FAGRO.BR

Latest Trade

18.79EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

13.43

 - 

19.19

As of on the Euronext Brussels ∙ Minimum 15 minute delay

Pricing

Previous Close
18.79
Open
--
Volume
--
3M AVG Volume
4.07
Today's High
--
Today's Low
--
52 Week High
19.19
52 Week Low
13.43
Shares Out (MIL)
71.74
Market Cap (MIL)
1,356.24
Forward P/E
26.72
Dividend (Yield %)
0.45

Latest Developments

More

Fagron Reports Norges Bank Shareholding Beyond Disclosure Threshold Of 3%

Fagron Increases Share Capital Through Warrant Exercises to EUR 496.5 Mln

Waterland And Baltisse Announces Private Placement Of Around 9.3 Million Shares In Fagron

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Fagron NV

Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. It operates as a research and development (R&D) scientific pharmaceutical compounding supplier and operates through four segments: The Fagron Specialty Pharma Services segment comprises personalized medication that is produced in the Company's compounding facilities; the Fagron Trademarks segment encompasses concepts and formulations developed by the Company's research and development (R&D) team; Fagron Essentials comprises pharmaceutical raw materials, equipment and supplies for pharmacies, and the HL Technology segment includes the development and production of precision components and orthopedic tools for dental and medical professionals.

Industry

Medical Equipment & Supplies

Contact Info

Venecoweg 20A

+32.80.012880

https://fagron.com/

Executive Leadership

Koen Hoffman

Independent Chairman of the Board representing AHOK BVBA

Rafael Padilla

Chief Executive Officer, Member of the Executive Committee, Director

Karin de Jong

Chief Financial Officer, Executive Director, Member of the Executive Committee

Constantijn van Rietschoten

Chief Communications Officer, Member of the Executive Committee

Marc Coucke

Director representing Alychlo NV

Key Stats

1.43 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.4K

2017

0.4K

2018

0.5K

2019(E)

0.5K
EPS (EUR)

2016

0.550

2017

0.650

2018

0.590

2019(E)

0.734
Price To Earnings (TTM)
26.44
Price To Sales (TTM)
2.73
Price To Book (MRQ)
6.30
Price To Cash Flow (TTM)
18.08
Total Debt To Equity (MRQ)
173.69
LT Debt To Equity (MRQ)
157.75
Return on Investment (TTM)
9.83
Return on Equity (TTM)
7.10

Latest News

Latest News

Belgium's Fagron to expand into Mexico with Cedrosa buy

Belgian pharmaceutical ingredients group Fagron NV said on Monday it was acquiring Central de Drogas, S.A. de C.V. (Cedrosa) in a 352 million Mexican pesos ($18.39 million) cash deal to expand further its presence in Latin America.

Belgium's Fagron to expand into Mexico with Cedrosa buy

Belgian pharmaceutical ingredients group Fagron NV said on Monday it was acquiring Central de Drogas, S.A. de C.V. (Cedrosa) in a 352 million Mexican pesos ($18.39 million) cash deal to expand further its presence in Latin America.

BRIEF-Fagron Reports Q1 Turnover At 109.1 Million Euros

* Q1 TURNOVER EUR 109.1 MILLION VERSUS EUR 109.0 MILLION YEAR AGO

BRIEF-Humco And Fagron To Combine For Up To 70 Million Dollars

* GREGORY PULIDO, HUMCO'S CHAIRMAN AND CHIEF EXECUTIVE OFFICER, WILL TRANSITION TO ROLE OF EXECUTIVE CHAIRMAN

BRIEF-Fagron Acquires Humco in United States

* FAGRON STRENGTHENS STRATEGIC POSITION IN USA THROUGH HIGHLY COMPLEMENTARY ACQUISITION OF HUMCO

BRIEF-Fagron FY Rebitda Increased 5.7% To 95.7 Million Euros

* REG-FAGRON TURNOVER INCREASED BY 3.6% TO € 436.9 MILLION AND NET PROFIT INCREASED TO € 47.0 MILLION

BRIEF-Cannimed Therapeutics Announces Cannabis Distribution Agreement With Fagron NV

* CANNIMED THERAPEUTICS INC. ANNOUNCES STRATEGIC INTERNATIONAL CANNABIS DISTRIBUTION AGREEMENT WITH FAGRON NV

BRIEF-Fagron appoints ‍Rafael Padilla to succeed Hans Stols as CEO

* MR. STOLS WILL RESIGN FROM ALL HIS FUNCTIONS AND MANDATES WITH IMMEDIATE EFFECT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Fagron Q3 turnover up at 103.6 million euros

* Q3 TURNOVER EUR 103.6 MILLION VERSUS EUR 103.4 MILLION YEAR AGO

BRIEF-Fagron acquires All Chemistry in Brazil

* FAGRON FURTHER EXECUTES BUY-AND-BUILD STRATEGY WITH ACQUISITION OF ALL CHEMISTRY IN BRAZIL Source text: http://bit.ly/2yJwvbB Further company coverage: (Gdynia Newsroom)

Pharma ingredients group Fagron reports 27 pct profit increase

Pharmaceutical ingredients company Fagron said it was focusing on off-the-shelf products to boost its margins, especially in Brazil, after reporting a 27 percent increase in first-half profit.

BRIEF-Fagron H1 ‍net profit increases 27.0 pct to 21.1 million euros

* H1 REBITDA INCREASES 5.6% TO EUR 48.1 MILLION OR 21.7% OF TURNOVER

BRIEF-Fagron redeems bond loan of 225 million euros

* BOND LOAN OF EUR 225 MILLION WILL BE REDEEMED IN FULL TODAY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Fagron Q1 revenue increases by 7.1 pct to 109.9 million euros

* Turnover increases by 7.1 pct to 109.9 million euros ($117.29 million)

BRIEF-Fagron realises FY turnover of 421.8 mln euros, 1.3 pct down

* Fagron realises turnover of 421.8 million euros ($451.75 million)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up